For almost 20 years, cell therapy has been touted as a natural solution to replace
heart muscle lost at the time of myocardial infarction.
1
,
2
,
3
But recent scandals
4
and failed clinical trials
5
have done little to inspire confidence in a jaded medical community. Although a portion
of the blame lies in the early hype and hyperbole raising unrealistic expectations,
some of the initial mechanisms that assumed how transplanted cells would modify heart
function have proved to be spectacularly wrong and prompted many to consider new directions
to restore injured tissue.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Myocyte death, growth, and regeneration in cardiac hypertrophy and failure.Circ Res. 2003; 92: 139-150
- Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy.Proc Natl Acad Sci USA. 2003; 100: 10440-10445
- Bone marrow cells regenerate infarcted myocardium.Nature. 2001; 410: 701-705
- Cardiac stem cells in the post-Anversa era.Eur Heart J. 2019; 40: 1039-1041
- Autologous bone marrow stem cell therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis.Can J Cardiol. 2017; 33: 1611-1623
- Myoblast transplantation for heart failure.Lancet. 2001; 357: 279-280
- Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction.J Am Coll Cardiol. 2003; 41: 1078-1083
- Electrical effects of stem cell transplantation for ischaemic cardiomyopathy: friend or foe?.J Physiol. 2016; 594: 2511-2524
- The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation.Circulation. 2008; 117: 1189-1200
- A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction.Am Heart J. 2011; 162: 654-662
- Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium.J Exp Med. 2006; 203: 2315-2327
- Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.Nat Biotechnol. 2007; 25: 1015-1024
- Noninvasive tracking of cardiac embryonic stem cells in vivo using magnetic resonance imaging techniques.Stem Cells. 2007; 25: 2936-2944
- Systems approaches to preventing transplanted cell death in cardiac repair.J Mol Cell Cardiol. 2008; 45: 567-581
- Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts.Nature. 2012; 489: 322-325
- Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts.Nature. 2014; 510: 273-277
- CD34+ stem cells: promising roles in cardiac repair and regeneration.Can J Cardiol. 2019; 35: 1311-1321
- Cardiomyocyte regeneration: a consensus statement.Circulation. 2017; 136: 680-686
- The secret life of exosomes: what bees can teach us about next-generation therapeutics.J Am Coll Cardiol. 2018; 71: 193-200
- A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.J Am Coll Cardiol. 2009; 54: 2277-2286
- ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial: rationale and design.Cell Transplant. 2017; 26: 205-214
- The RENEW trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.J Am Coll Cardiol Cardiovasc Intv. 2016; 9: 1576-1585
Article info
Publication history
Published online: July 10, 2019
Accepted:
July 7,
2019
Received:
July 3,
2019
Footnotes
See article by Marvasti et al., pages 1311–1321 of this issue.
See page 1279 for disclosure information.
Identification
Copyright
© 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- CD34+ Stem Cells: Promising Roles in Cardiac Repair and RegenerationCanadian Journal of CardiologyVol. 35Issue 10
- PreviewCell therapy has received significant attention as a novel therapeutic approach to restore cardiac function after injury. CD34-positive (CD34+) stem cells have been investigated for their ability to promote angiogenesis and contribute to the prevention of remodelling after infarct. However, there are significant differences between murine and human CD34+ cells; understanding these differences might benefit the therapeutic use of these cells. Herein we discuss the function of the CD34 cell and highlight the similarities and differences between murine and human CD34 cell function, which might explain some of the differences between the animal and human evolutions.
- Full-Text
- Preview
